Cited by

• Secondary prophylaxis of venous thromboembolism (VTE) with low dose apixaban or rivaroxaban in major-thrombophilia carriers.

  Laganà A, Sorella S, Fucci L, Santoro C, Ligia S, Mormile R, Baldacci E, Chistolini A. Laganà A, et al. Ann Hematol. 2024 Nov;103(11):4731-4739. doi: 10.1007/s00277-024-06021-2. Epub 2024 Oct 8. Ann Hematol. 2024. PMID: 39379551
• Clinical characteristics and thrombophilia associated gene variants in Egyptians with unprovoked venous thromboembolism: three centers experience.

  Efat A, Shoeib S, Abdelmonem AA, Elamawy MM, Eleleimy HA, Ibrahem RA, Elmorshedy SM, Abdelaty MM. Efat A, et al. Mol Biol Rep. 2024 Sep 26;51(1):1013. doi: 10.1007/s11033-024-09909-4. Mol Biol Rep. 2024. PMID: 39325233
• Chronic thromboembolic pulmonary hypertension: the diagnostic assessment.

  Simeone B, Maggio E, Schirone L, Rocco E, Sarto G, Spadafora L, Bernardi M, Ambrosio L, Forte M, Vecchio D, Valenti V, Sciarretta S, Vizza CD. Simeone B, et al. Front Cardiovasc Med. 2024 Sep 6;11:1439402. doi: 10.3389/fcvm.2024.1439402. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39309600 Free PMC article. Review.
• Management of Thrombosis in a Patient with Three Thrombophilic Disorders.

  Marco-Rico A, Mantilla Pinilla AJ, Corral J, Marco-Vera P. Marco-Rico A, et al. J Blood Med. 2024 Jul 24;15:305-312. doi: 10.2147/JBM.S466335. eCollection 2024. J Blood Med. 2024. PMID: 39070969 Free PMC article.
• The Etiology of the Thrombotic Phenomena Involved in the Process of Coronary Artery Disease-What Is the Role of Thrombophilic Genes in the Development of This Pathology?

  Bararu Bojan I, Dobreanu S, Vladeanu MC, Ciocoiu M, Badescu C, Plesoianu C, Filip N, Iliescu D, Frasinariu O, Bojan A, Tudor R, Badulescu OV. Bararu Bojan I, et al. Int J Mol Sci. 2024 May 11;25(10):5228. doi: 10.3390/ijms25105228. Int J Mol Sci. 2024. PMID: 38791267 Free PMC article. Review.